With this concept in mind, we prospectively assessed thyroid status (thyroid function, autoimmunity and ultrasound features) in a cohort of HCV patients, subdivided in naïve and previously treated with IFN-α and ribavirin, before and after DAAs therapy. This evidence concerns the gene IFNA17 and thyroiditis.